Report Description Table of Contents Endometriosis Treatment Market: Hormonal Therapies Lead as Non-Hormonal Innovation Advances – (Updated On: 22nd-Sep-2026) The Global Endometriosis Treatment Market is expanding due to the high disease burden, prolonged diagnosis timelines, and increasing demand for therapies that improve pain management, fertility outcomes, and quality of life. The market was valued at USD 2.03 billion in 2025 and is projected to reach USD 4.00 billion by 2032, expanding at a CAGR of 10.25% during 2026–2032. Endometriosis affects approximately 10% of reproductive-age women and girls globally, representing nearly 190 million individuals, creating a substantial long-term treatment need. In the United States, the condition affects around 11% of women aged 15–44 years, representing more than 6.5 million individuals. Despite the large patient population, diagnosis remains a major challenge, with patients experiencing an average diagnostic delay of 6–10 years and often consulting five or more healthcare providers before receiving confirmation. The clinical burden of endometriosis extends beyond pelvic pain, with approximately 50%–80% of patients experiencing pelvic pain and 30%–50% experiencing infertility-related complications. The condition is also associated with significant daily impairment, with up to 68% of patients reporting disruption to work, education, or routine activities. Additionally, endometriosis contributes to a major economic burden, with annual medical and out-of-pocket costs averaging around USD 14,000 per patient. Treatment approaches are primarily focused on symptom control, disease management, and fertility preservation through a combination of hormonal therapies, pain management, and surgical interventions. Hormonal treatments, including oral GnRH antagonists such as Orilissa (elagolix) and Myfembree (relugolix combination therapy), GnRH agonists, hormonal contraceptives, and progestin-based therapies, remain key pharmaceutical approaches for reducing estrogen-driven disease activity. Surgical management continues to play an important role, particularly for patients with severe disease or fertility-related concerns. Laparoscopic excision and ablation procedures are widely used, with experienced specialists reporting 70%–90% symptom improvement following laparoscopic surgery. However, recurrence remains a challenge, with reported recurrence rates of approximately 20%–30% and long-term reoperation rates reaching up to 50% in some patient populations. The treatment landscape is gradually shifting toward precision and disease-modifying approaches beyond traditional hormonal suppression. Emerging therapies such as ENDO-205, a non-hormonal lesion-targeted peptide therapy designed to directly address endometriosis lesions, and FemLUNA, an investigational precision imaging approach for non-invasive disease detection, represent efforts to improve diagnosis and treatment specificity. Research into alternative approaches, including GLP-1 receptor agonists for inflammation-related symptoms, remains exploratory and requires further clinical validation. Overall, the endometriosis treatment market is being shaped by the large untreated and underdiagnosed patient population, unmet needs in long-term symptom control, fertility preservation challenges, and increasing development of targeted non-hormonal therapies. Future growth will depend on reducing diagnostic delays, improving treatment durability, and advancing therapies that address the underlying disease mechanisms rather than only managing symptoms. Key Report Takeaways—Procedure Mix and Advanced Surgical Technologies Shape Revenue Growth By Surgical Procedure Lobectomy accounts for a 67.6% share, equivalent to USD 4.293 billion in 2025 revenue, and is projected to expand at a CAGR of 5.95% during 2026–2032. Wedge Resection represents a 20.5% share, generating USD 1.302 billion in 2025 revenue, and is expected to grow at a CAGR of 5.45% during 2026–2032. Segmentectomy holds a 9.7% share, corresponding to USD 0.616 billion in 2025 revenue, and is projected to record the fastest procedure CAGR of 11.45% during 2026–2032. Sleeve Resection, Pneumonectomy, and Other Procedures collectively account for a 2.2% share, equivalent to USD 0.140 billion in 2025 revenue, and are projected to expand at a CAGR of 3.85% during 2026–2032. By Surgical Approach Video-Assisted Thoracoscopic Surgery (VATS) holds a 43% share, representing USD 2.731 billion in 2025 revenue, and is projected to expand at a CAGR of 6.25% during 2026–2032. Robotic-Assisted Thoracic Surgery (RATS) accounts for a 19% share, equivalent to USD 1.207 billion in 2025 revenue, and is expected to record the fastest approach CAGR of 11.35% during 2026–2032. Open Thoracotomy represents a 38% share, corresponding to USD 2.413 billion in 2025 revenue, and is projected to grow at a CAGR of 3.95% during 2026–2032. By Product Type Surgical Devices and Instruments account for a 59% share, generating USD 3.747 billion in 2025 revenue, and are projected to expand at a CAGR of 5.85% during 2026–2032. Monitoring and Visualization Equipment represents a 23% share, equivalent to USD 1.461 billion in 2025 revenue, and is expected to record the fastest product CAGR of 8.45% during 2026–2032. Endosurgical and Access Equipment holds an 18% share, corresponding to USD 1.143 billion in 2025 revenue, and is projected to grow at a CAGR of 5.35% during 2026–2032. By End User Hospitals hold a dominant 74% share, representing USD 4.699 billion in 2025 revenue, and are projected to expand at a CAGR of 5.95% during 2026–2032. Specialty Cancer and Thoracic Surgery Centers account for an 18% share, equivalent to USD 1.143 billion in 2025 revenue, and are expected to grow at a CAGR of 7.15% during 2026–2032. Ambulatory Surgical Centers represent an 8% share, corresponding to USD 0.508 billion in 2025 revenue, and are projected to record the fastest end-user CAGR of 8.25% during 2026–2032. By Geography North America holds a 40% share, representing USD 2.540 billion in 2025 revenue, and is projected to expand at a CAGR of 5.45% during 2026–2032. Europe accounts for a 28% share, equivalent to USD 1.778 billion in 2025 revenue, and is expected to grow at a CAGR of 5.75% during 2026–2032. Asia-Pacific represents a 24% share, corresponding to USD 1.524 billion in 2025 revenue, and is projected to record the fastest regional CAGR of 8.50% during 2026–2032. Latin America contributes a 5% share, equivalent to USD 0.318 billion in 2025 revenue, and is expected to expand at a CAGR of 6.60% during 2026–2032. Middle East & Africa accounts for a 3% share, representing USD 0.191 billion in 2025 revenue, and is projected to grow at a CAGR of 6.00% during 2026–2032. Segment Leadership—Established Categories Retain Scale as Emerging Segments Accelerate 2025 Revenue Leaders—Large Procedure and Care-Setting Segments Anchor the Market Procedure Revenue Leader: Lobectomy Lobectomy accounts for a dominant 67.6% market share, generating approximately USD 4.293 billion in revenue in 2025, and is expected to expand at a CAGR of 5.95% from 2026 to 2032. In endometriosis management, lobectomy remains a rare, second-line surgical intervention, primarily reserved for severe thoracic endometriosis syndrome cases involving localized pulmonary parenchymal disease. It is considered when hormonal therapies fail, lesions are deeply confined to a lung lobe, or diagnostic uncertainty requires definitive pathological evaluation. Approach Revenue Leader: Video-Assisted Thoracoscopic Surgery Video-Assisted Thoracoscopic Surgery (VATS) dominates the market with a 43% share, generating USD 2.731 billion in revenue in 2025, and is expected to expand at a CAGR of 6.25% from 2026 to 2032. VATS is considered a gold-standard minimally invasive technique for diagnosing and managing thoracic endometriosis. It enables surgeons to identify and treat endometrial lesions within the chest cavity through small incisions using a camera and specialized instruments. The procedure supports lesion excision, ablation, diaphragm or lung repair, and pleurodesis to reduce recurrence of complications such as pneumothorax. Product Revenue Leader: Surgical Devices and Instruments Surgical devices and instruments represent the largest segment of the endometriosis treatment market, accounting for 59% share and generating USD 3.747 billion in 2025 revenue, with an expected CAGR of 5.85% from 2026 to 2032. These tools are essential in laparoscopic procedures, enabling surgeons to accurately visualize, excise, and manage endometrial lesions while minimizing damage to surrounding tissues. Key technologies include advanced laparoscopes, precision graspers, energy-based devices, suction systems, and robotic platforms that enhance surgical accuracy and outcomes. End-User Revenue Leader: Hospitals Hospitals dominate with a 74% share, representing USD 4.699 billion in 2025 revenue, and are projected to expand at a CAGR of 5.95% during 2026–2032. Their revenue is approximately 2.8 times the combined USD 1.651 billion attributed to specialty centers and ambulatory surgical centers. The supplied CAGR implies approximately USD 7.042 billion in hospital revenue by 2032, adding USD 2.343 billion. This concentration makes hospital demand the largest contributor to revenue within the end-user segmentation. Regional Revenue Leader: North America North America leads the endometriosis treatment market, accounting for nearly 40% of global revenue with approximately USD 2.540 billion in 2025. The region’s position is supported by the high diagnosed patient pool, strong adoption of advanced hormonal therapies, laparoscopic endometriosis procedures, and increasing utilization of specialized gynecology and fertility care services. The presence of approved treatments such as GnRH antagonists including Orilissa (elagolix) and Myfembree (relugolix combination therapy), along with established reimbursement pathways for medical and surgical management, continues to support treatment adoption. The region is projected to expand at a CAGR of 5.45% during 2026–2032. Growth Leaders—Smaller Segments Gain Commercial Relevance Through Faster Expansion Fastest-Growing Procedure: Segmentectomy Segmentectomy is the fastest-growing procedure category, with a projected CAGR of 11.45% during 2026–2032. It holds a 9.7% share, corresponding to USD 0.616 billion in 2025 revenue. Its growth rate exceeds lobectomy by 5.50 percentage points and wedge resection by 6.00 percentage points. Applying this CAGR implies approximately USD 1.316 billion in revenue by 2032, a cumulative increase of 113.6%, or approximately USD 700 million. This trajectory increases its commercial significance from a comparatively small starting base. Fastest-Growing Approach: Robotic-Assisted Thoracic Surgery Robotic-Assisted Thoracic Surgery (RATS) is projected to register the highest approach CAGR of 11.35% from 2026 to 2032, expanding from a 19% market share and USD 1.207 billion revenue in 2025. Beyond general thoracic procedures, RATS offers a highly specialized approach for rare thoracic endometriosis cases involving diaphragmatic or chest cavity lesions. Its 3D visualization, enhanced access, wristed instruments, tremor reduction, and improved operative space enable precise identification, dissection, and repair of complex endometrial implants near critical thoracic structures. Fastest-Growing Product Category: Monitoring and Visualization Equipment Monitoring and Visualization Equipment is expected to be the fastest-growing product segment, registering a projected CAGR of 8.45% from 2026 to 2032. These advanced technologies enable clinicians to accurately visualize, map, and target endometriosis lesions, supporting precise diagnosis, surgical planning, and real-time intraoperative decision-making. Non-invasive imaging modalities such as transvaginal ultrasound (TVUS) and MRI help detect and characterize lesions, while advanced tracers enhance lesion identification. During surgery, laparoscopes and robotic-assisted systems provide magnified, high-definition visualization, enabling precise tissue removal while minimizing damage to surrounding structures. Fastest-Growing End User: Ambulatory Surgical Centers Ambulatory Surgical Centers (ASCs) are emerging as the fastest-growing end-user segment in the endometriosis treatment market, with a projected CAGR of 8.25% from 2026–2032, accounting for an 8% market share and generating USD 0.508 billion in revenue in 2025. ASCs support routine and minimally invasive procedures, enabling same-day discharge and improved efficiency. They are particularly suitable for younger, lower-risk patients with localized disease, while complex multi-organ endometriosis cases continue to require hospital-based care. Fastest-Growing Region: Asia-Pacific Asia-Pacific is projected to be the fastest-growing region in the endometriosis treatment market, expanding at a CAGR of 8.50% during 2026–2032 and accounting for approximately 24% of global revenue, generating USD 1.524 billion in 2025. Growth is driven by increasing recognition of endometriosis as a chronic gynecological condition, reduction in delayed diagnosis, and rising demand for non-surgical treatment options such as hormonal therapies and pain management approaches. The region is also witnessing greater adoption of minimally invasive laparoscopic procedures and fertility-focused endometriosis management as healthcare systems improve access to specialized gynecological services. Market Growth Drivers—Diagnosis Expansion, Oral Therapies, and Non-Hormonal Research Increase Treatment Demand Large Disease Burden and Improved Diagnosis Expand the Treated Population Endometriosis affects approximately 10% of reproductive-age women and girls, representing nearly 190 million people worldwide. In the United States, more than 6.5 million women aged 15–44 years, or approximately 11% of that population, are estimated to have the condition. Because endometriosis is chronic and currently has no definitive cure, patients may require recurring medication, diagnostic imaging, specialist consultations, fertility services, and surgical care over several years. This large continuing patient population supports long-term demand across pharmaceutical and procedural treatment categories. Shorter Diagnostic Pathways Increase Treatment Eligibility The World Health Organization reports that obtaining an endometriosis diagnosis can take an average of 4–12 years. Wider use of symptom-based clinical assessment, transvaginal ultrasound, and MRI can help identify suspected disease without requiring every patient to undergo diagnostic surgery. Research is also advancing blood-, saliva-, and menstrual-blood-based tests intended to support earlier and less invasive detection. Reducing the diagnostic delay can move patients into medical treatment, pain management, fertility counseling, and specialist care earlier, expanding the commercially treated population. Oral GnRH Therapies Provide Measurable Symptom Improvement The availability of oral GnRH antagonists provides a more convenient alternative to traditional injectable suppression therapies. In two pivotal 24-week studies of Myfembree, 74.5% and 75.1% of treated patients achieved a clinically meaningful reduction in dysmenorrhea, compared with 26.9% and 30.5% receiving placebo. Clinically meaningful improvement in non-menstrual pelvic pain was recorded in 58.5% and 65.9% of treated patients, compared with 39.6% and 42.5% of placebo recipients. These outcomes support continued adoption of oral combination therapies among patients requiring stronger symptom control than conventional contraceptive or progestin treatment can provide. Hormonal Safety Limitations Increase Demand for Non-Hormonal Therapies Long-term hormonal suppression can be restricted by bone-density loss, menopausal symptoms, treatment-duration limits, and incompatibility with immediate pregnancy plans. In Myfembree clinical data, a reduction of more than 3% in lumbar-spine bone mineral density after 12 months occurred in 19.7% of treated patients, compared with 9.1% in an untreated observational cohort. The product’s use is limited to 24 months because bone loss may not be completely reversible. These limitations strengthen the development case for non-hormonal therapies capable of controlling inflammation, pain, and lesion activity without prolonged estrogen suppression. Public Funding and Research Partnerships Support Precision Diagnosis Public research programs are increasing the resources available for endometriosis diagnostics and personalized care. The European Union’s FEMaLe—Finding Endometriosis Using Machine Learning project received approximately EUR 5.94 million in EU funding under Horizon 2020. The project applied clinical data, patient-reported information, genetics, machine learning, and precision-medicine tools to improve early detection and disease management. Programs of this scale support biomarker validation, shared clinical datasets, academic-industry collaboration, and the development of future diagnostic and treatment platforms. Competitive Landscape—Robotic Platforms and Surgical Instruments Define Market Positioning Intuitive Surgical—Robotic Scale Supports Recurring Instrument Revenue Intuitive Surgical is a prominent company in robotic-assisted lung surgery through its da Vinci surgical systems, which support lobectomy, segmentectomy, and wedge resection. Its thoracic portfolio combines wristed instruments, SureForm staplers, and Firefly fluorescence imaging, giving hospitals an integrated platform for minimally invasive lung procedures. According to its 2025 Annual Report, Intuitive generated approximately USD 10.1 billion in revenue, up 21% from 2024. Surgeons performed more than 3.1 million da Vinci procedures in 2025, representing 18% annual growth. The company ended the year with more than 11,100 installed da Vinci systems, placed 1,721 systems during 2025, and invested over USD 1 billion in research and development. For the lung surgery market, this installed base provides a foundation for thoracic program adoption and recurring demand for instruments, accessories, and maintenance. Its competitive position rests on the combination of equipment availability, procedure-specific tools, and surgeon training. However, the reported financial and operating figures cover multiple surgical specialties; they do not establish Intuitive as the number-one company by total lung surgery revenue. Other Companies Supporting Surgical Delivery Medtronic: Supplies Signia and Tri-Staple stapling systems, LigaSure vessel-sealing devices, and thoracic access instruments used in lung resection and tissue management. Johnson & Johnson MedTech: Provides ECHELON staplers and reloads for tissue transection and closure during lobectomy, segmentectomy, and wedge resection. KARL STORZ: Offers thoracic endoscopes, visualization systems, and surgical instruments supporting minimally invasive thoracic procedures. Analyst Commentary—Long-Term Tolerability Will Define Endometriosis Treatment Leadership The endometriosis treatment market’s next competitive opportunity lies in therapies that combine sustained symptom control with acceptable long-term tolerability. Based on the supplied estimates, hormonal therapies account for 79% of revenue, while GnRH-based treatments represent 52% of the total market, placing differentiation within hormonal treatment at the center of competition. Oral convenience alone is unlikely to secure durable adoption; affordability, treatment persistence, and side-effect management will influence commercial success. Non-hormonal therapies offer a potential route to serve patients whose needs remain inadequately addressed, provided developers demonstrate meaningful clinical benefits. Endometriosis Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 2.03 Billion Revenue Forecast in 2032 USD 4.00 Billion Overall Growth Rate CAGR of 10.25% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Surgical Procedure, By Surgical Approach, By Product Type, By End User, By Geography By Surgical Procedure Lobectomy, Wedge Resection, Segmentectomy, Sleeve Resection, Pneumonectomy, Other Procedures By Surgical Approach Video-Assisted Thoracoscopic Surgery (VATS), Robotic-Assisted Thoracic Surgery (RATS), Open Thoracotomy By Product Type Surgical Devices and Instruments, Monitoring and Visualization Equipment, Endosurgical and Access Equipment By End User Hospitals, Specialty Cancer and Thoracic Surgery Centers, Ambulatory Surgical Centers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Large underdiagnosed patient population, prolonged diagnostic timelines, recurring demand for hormonal treatment, rising adoption of oral GnRH therapies, increasing minimally invasive surgical procedures, fertility-preservation needs, and development of targeted non-hormonal therapies Customization Option Available upon request Frequently Asked Question About This Report Q1. What is expanding the treated population in this market? A1. Greater disease awareness and wider use of ultrasound and MRI are helping more patients enter treatment. Endometriosis affects nearly 190 million women and girls worldwide, yet many remain undiagnosed. Improving detection supports growth from USD 2.03 billion in 2025 to USD 4.00 billion by 2032. Q2. Why do diagnostic delays remain a major industry constraint? A2. Diagnosis commonly takes 6–10 years and patients may consult five or more healthcare providers before receiving confirmation. This delay postpones pain management, fertility counseling, and specialist treatment. It also limits the number of patients receiving appropriate long-term care. Q3. How are oral GnRH therapies changing treatment demand in this market? A3. Oral GnRH antagonists offer an alternative to injectable hormone suppression for patients requiring stronger symptom control. In Myfembree trials, about 75% of treated patients achieved meaningful dysmenorrhea improvement. Adoption still depends on treatment duration limits and bone-density monitoring. Q4. What is creating room for non-hormonal innovation across the industry? A4. Hormonal treatments can cause menopausal symptoms and bone-density loss. They may also conflict with immediate pregnancy plans. Candidates such as ENDO-205 aim to address lesions without prolonged hormonal suppression, although broader adoption will require convincing clinical evidence. Q5. Why does surgery remain important despite pharmaceutical growth in this market? A5. Laparoscopic excision and ablation remain important for severe disease, persistent pain, and fertility-related complications. Experienced specialists report symptom improvement in 70%–90% of patients. However, recurrence rates of 20%–30% and substantial reoperation risk sustain demand for longer-lasting alternatives. Q6. How are fertility considerations influencing the industry’s treatment pathway? A6. Around 30%–50% of patients experience infertility-related complications. Treatment must therefore balance pain control and disease suppression with reproductive plans. This need increases demand for fertility specialists, advanced imaging, laparoscopic surgery, and individualized medication strategies. Q7. What will determine future competitive success in this market? A7. Successful therapies will need to provide durable symptom relief without creating unacceptable long-term safety risks. Affordability, treatment persistence, fertility compatibility, and evidence of disease modification will influence adoption. Non-hormonal products could gain a stronger position if they demonstrate clear clinical benefits. Sources: World Health Organization—Endometriosis Fact Sheet U.S. Office on Women’s Health—Endometriosis Overview American College of Obstetricians and Gynecologists—Endometriosis Diagnosis and Treatment ESHRE—Guideline on Endometriosis NICE—Endometriosis Diagnosis and Management Recommendations NHS—Endometriosis Symptoms, Diagnosis, and Treatment Cleveland Clinic—Endometriosis Diagnosis and Treatment DailyMed—Myfembree Prescribing Information AbbVie—Orilissa Prescribing and Safety Information The Lancet—SPIRIT 1 and SPIRIT 2 Relugolix Combination-Therapy Trials NICE—Relugolix Combination Therapy for Endometriosis European Commission CORDIS—FEMaLe Endometriosis Machine-Learning Project FEMaLe Project—Finding Endometriosis Using Machine Learning Human Reproduction Update—Endometriosis as an Estrogen-Dependent Disease Table of Contents - Global Endometriosis Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Surgical Procedure, Surgical Approach, Product Type, End User, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Surgical Procedure, Surgical Approach, Product Type, End User, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Surgical Procedure, Surgical Approach, Product Type, and End User Investment Opportunities in the Endometriosis Treatment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Minimally Invasive Endometriosis Procedures, Robotic-Assisted Surgical Technologies, Advanced Visualization Systems, Fertility-Focused Care, Hormonal Therapies, and Non-Hormonal Treatment Development Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Endometriosis Diagnosis, Symptom Management, Fertility Preservation, Minimally Invasive Surgery, and Long-Term Disease Management Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Diagnostic Delays, Treatment Accessibility, Hormonal Safety, and Fertility Considerations Role of Laparoscopic Procedures, Video-Assisted Thoracoscopic Surgery, Robotic-Assisted Thoracic Surgery, Open Surgical Management, and Advanced Visualization in Endometriosis Care Clinical Innovation, Non-Hormonal Research, Precision Diagnosis, and Long-Term Treatment Tolerability Trends Global Endometriosis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Surgical Procedure: Lobectomy Wedge Resection Segmentectomy Sleeve Resection Pneumonectomy Other Procedures Market Analysis by Surgical Approach: Video-Assisted Thoracoscopic Surgery (VATS) Robotic-Assisted Thoracic Surgery (RATS) Open Thoracotomy Market Analysis by Product Type: Surgical Devices and Instruments Monitoring and Visualization Equipment Endosurgical and Access Equipment Market Analysis by End User: Hospitals Specialty Cancer and Thoracic Surgery Centers Ambulatory Surgical Centers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Endometriosis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Surgical Procedure, Surgical Approach, Product Type, and End User Country-Level Breakdown: United States Canada Mexico Europe Endometriosis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Surgical Procedure, Surgical Approach, Product Type, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Endometriosis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Surgical Procedure, Surgical Approach, Product Type, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Endometriosis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Surgical Procedure, Surgical Approach, Product Type, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Endometriosis Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Surgical Procedure, Surgical Approach, Product Type, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Intuitive Surgical, Inc. Medtronic plc Johnson & Johnson MedTech KARL STORZ SE & Co. KG AbbVie Inc. Pfizer Inc. Organon & Co. Bayer AG Competitive Landscape and Strategic Insights Benchmarking Based on Therapeutic Portfolio, Surgical Technology, Minimally Invasive Capabilities, Product Innovation, Diagnostic Support, Clinical Evidence, Distribution Network, and Regional Presence Endometriosis Treatment Portfolio and Clinical Development Capability Analysis Hormonal Therapy Positioning and Long-Term Treatment Strategy Analysis Non-Hormonal Therapy and Precision Treatment Development Minimally Invasive Surgical Technology, Advanced Visualization, and Robotic-Assisted Procedure Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Surgical Procedure, Surgical Approach, Product Type, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Therapeutic, Surgical, Diagnostic, and Treatment Access Analysis Technology Adoption Trends Across Video-Assisted Thoracoscopic Surgery, Robotic-Assisted Thoracic Surgery, Open Thoracotomy, Surgical Devices and Instruments, Monitoring and Visualization Equipment, and Endosurgical and Access Equipment List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Surgical Procedure, Surgical Approach, Product Type, and End User (2025 vs. 2032) Global Endometriosis Treatment Ecosystem and Value Chain Analysis